tamoxifen / Generic mfg. - LARVOL DELTA

Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial. (PubMed, EBioMedicine) - P3 | "Tamoxifen intake in the evening/nighttime could be recommended in patients with high-risk HR+/HER2- BC while awaiting for results from further ET timing studies."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Preoperative window-of-opportunity study with giredestrant or tamoxifen (tam) in premenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) and Ki67≥10% early breast cancer (EBC): The EMPRESS study (ESMO 2025) - P2 | "Additional endpoints will be reported at the meeting. Conclusions Giredestrant, administered without LHRH analogs, demonstrated superior antiproliferative activity than tam in terms of Ki67 reduction in premenopausal women with ER+/HER2- EBC."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative (LORETTA trial: JCOG1505) (SABCS 2025) - "The primary endpoint did not meet the predefined threshold. However, the incidence of ipsilateral invasive breast cancer and the surgical proportion were low at 5 years. TAM alone without surgery therapy might be an option in carefully selected low-risk DCIS with ER-positive HER2-negtaive."

Surgery • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • ER • HER-2

Adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive/HER2-positive early breast cancer: An exploratory analysis from the ALTTO (BIG 2-06) trial (SABCS 2025) - "The present analysis investigated the efficacy of different types of ET in pts with centrally tested HR+/HER2+ EBC treated with modern chemotherapy (CT) and trastuzumab (T)-based regimens at 10-year follow-up.Patients and ALTTO (BIG 2-06) is an international phase 3 trial in pts with HER2+ EBC randomized to 4 adjuvant anti-HER2 treatments with CT: T alone, lapatinib (L) alone, their sequence (T->L) or their combination (T+L). In this large 10-year follow-up analysis of pts with centrally tested HR+/HER2+ EBC treated with modern CT+anti-HER2-based therapy in the ALTTO trial, the use of AI was associated with significantly improved DFS and TTDR without differences in OS. The DFS benefit of AI was observed in both premenopausal and postmenopausal pts. These data may help optimizing adjuvant ET choices in pts with HR+/HER2+ EBC and shed light on the need of designing ad hoc clinical trials in this setting."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • HER-2

Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial (SABCS 2025) - P3 | "Giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), was shown to be more potent than other SERDs (Liang 2021; Bardia 2023) and demonstrated superior antiproliferative activity vs anastrozole in the neoadj coopERA BC trial (Hurvitz 2023)... Pts with Stage I-III ER+ HER2- eBC were randomized 1:1 to giredestrant 30 mg oral daily (with an LHRH agonist in pre- and peri-menopausal women, and men) or standard-of-care ET (tamoxifen or aromatase inhibitor) for 5 years (yr)... lidERA BC is the first Phase III trial to demonstrate benefit with an oral SERD in eBC. Giredestrant tx resulted in a statistically significant and clinically meaningful IDFS improvement vs standard-of-care ET in ER+, HER2- eBC. OS trended in favor of the giredestrant arm, and DRFI was improved vs standard-of-care ET."

Clinical • P3 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Nerve growth factor promotes the establishment of lung resident Th2+17 memory cells by supporting dopaminergic innervation (AAAAI 2026) - "NGF overexpression was initiated by tamoxifen treatment of CC10CreERT2; Rosa(NGF) mice around postnatal day 21 when the level of NGF starts to decrease before reaching a relatively low level in adults...Following HDM challenge, adult NGFOE Conclusions We identified a critical role of NGF in amplifying TRM(2+17) cells by sustaining dopaminergic innervation in the lung. These findings may inform pathogenesis of severe asthma in patients with elevated levels of NGF."

Asthma • Immunology • Inflammation • Respiratory Diseases • IL13 • IL17A • NGF

90 Days of Pre-Operative Endocrine Therapy Informs Patient and Physician Preference for Radiation Therapy: Primary Results from the Pre-Operative Window of Endocrine Therapy to Inform Radiation Therapy Decisions (POWER) Trial (ASBrS 2025) - "Ninety-five percent completed pre-ET (85.3%- aromatase inhibitor, 14.6%- tamoxifen)... Pre-ET significantly changed patient and surgeon preferences for RT and increased the agreement between patients' preferences and surgeons' recommendations. These findings validate pre-ET as an innovative method to inform adjuvant therapy decisions and recommendations by providing patients with the experience of taking ET prior to committing to adjuvant therapy. The forthcoming POWER II trial is designed to determine the impact of pre-ET on over- and under-treatment."

Clinical • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Fatigue • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Musculoskeletal Pain • Oncology • Solid Tumor • ER • HER-2 • PGR

The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer: Secondary analysis of an international cohort study. (ASCO 2025) - P | " Among 5,660 patients from 109 centers, 1,865 patients with HR+ BC were included, of whom 1,071 (57%) received OFS plus ET (35% with an aromatase inhibitor [AI], 65% with tamoxifen [tam]) and 794 (43%) received tam alone... In this global cohort of young BRCA mutation carriers, OFS combined with ET was associated with improved DFS, BCFI and OS versus tam without OFS. These findings support the consideration of OFS as a key component of adjuvant therapy in this population."

Clinical • Breast Cancer • Gynecology • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2 • HER-2

The WinPro trial: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer. (ASCO 2025) - P2 | "Patients (pts) were randomised 1:1:1 to letrozole (let) 2.5mg daily, letrozole 2.5mg daily + prometrium (pro) 300mg daily, or tamoxifen (tam) 20mg daily + prometrium 300mg daily for 11-17 days before surgery... The WinPro trial showed that the addition of pro to let in post-menopausal women with ER+, PR+, HER2- breast cancer was safe, reduced hot flushes and led to similar reduction in Ki67 as let alone. Ongoing translational analyses are underway which will examine the changes in gene expression in malignant, immune and stromal cells at sub-cellular resolution and provide further insight into the mechanisms of response and resistance to endocrine therapy."

Clinical • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • AR • ER • HER-2 • PGR

Opposing roles of endothelial versus smooth muscle Piezo1 in control of cerebrovascular tone. (ISC 2026) - "Endothelial Piezo1 deletion (EC Piezo1 KO) was induced by tamoxifen treatment of Cdh5(Pac)CreERT2; Piezo1 fl/fl mice...After one month, mice underwent intravital fluorescence imaging of leptomeningeal vasculature viewed through a thinned skull (Leica DMI8 microscope, isoflurane and heat support provided)...Additionally, our finding that Yoda 1 promotes vasoconstriction of cerebral arterioles in EC Piezo1 KO mice (particularly LMC arterioles) is consistent with an opposing constriction role of Piezo1 in the smooth muscle. We conclude that net effect of Piezo1 activation is determined by the balance of opposing effects from EC and SMC Piezo1 channels."

Cardiovascular • CDH5

Endothelial protease-activated receptor 1 deletion preserves the blood-brain barrier and enhances functional recovery after ischemic stroke (ISC 2026) - "Understanding how different components of the neurovascular unit contribute to BBB breakdown is essential for developing new treatments.Hypothesis: We hypothesized that the activation of protease-activated receptor 1 (PAR1) in endothelial cells exacerbates BBB breakdown after ischemic stroke, and targeted endothelial PAR1 deletion would improve outcomes. We used a novel endothelial cell-specific, tamoxifen-inducible PAR1 knockout (KO) mouse line (TIE2CreERT2PAR1f/f) in the current study... In conclusion, our results demonstrate a critical role of endothelial PAR1 in mediating BBB disruption after ischemic stroke. Specific deletion of endothelial PAR1 using TIE2 Cre preserves BBB integrity, reduces lesion volume and promotes functional recovery. Further studies are required to investigate the role of endothelial PAR1 on the regulation of tight junction integrity and neuroinflammation after stroke."

Cardiovascular • Hematological Disorders • Inflammation • Ischemic stroke

The Modified Zuojin Formula (SQQT) Associates ILC2-Linked JAK-2/STAT5/c-Myc Cascade and Gastric Metaplasia Regression. (PubMed, J Ethnopharmacol) - "The mechanism of SQQT protected the stomach from metaplasia associated to ILC2 activation and the subsequent cell proliferation through IL-5/JAK-2/STAT5/c-Myc pathway."

Journal • Inflammation • IL5 • JAK2 • MYC • STAT5 • STAT5AWqe • THY1

Tamoxifen Retinopathy and Macular Telangiectasia Type 2: Case-Based Differential Diagnosis. (PubMed, Beyoglu Eye J) - "One of the primary conditions considered in the differential diagnosis of TR is macular telangiectasia type 2 (Mac-Tel 2). In this case presentation, we aim to share the differential diagnosis process of TR and highlight the distinguishing features from Mac-Tel 2 in a female patient who presented with decreased vision, based on the patient's history, detailed fundoscopic examination findings, and multimodal imaging."

Journal • Achromatopsia • Breast Cancer • Oncology • Ophthalmology • Retinal Disorders • Solid Tumor

REGULATION OF COLONIC MACROPHAGES AND TYPE-17 AND REGULATORY T CELLS IN DSS-COLITIS BY IBD-ASSOCIATED TRANSCRIPTION FACTOR, CREM. (PubMed, bioRxiv) - "Mice were generated with either a tamoxifen-inducible global deletion or an intestinal epithelial cell (IEC)-specific deletion of Crem...Inducible global deletion of Crem reduced the severity of DSS colitis while increasing colonic macrophages, RORγt + regulatory (pTregs) and T helper (Th17) cells. Future work will investigate the aforementioned cell types to determine the mechanism by which CREM aggravates DSS-colitis, thereby defining the immunoregulatory role of CREM in intestinal inflammation with the goal of identifying new therapeutic targets for IBD."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • CREM

Observed tamoxifen drug interactions are dependent on both CYP2D6 phenotype and inhibitor potency. (PubMed, J Pharm Pharmacol) - "Patients on tamoxifen should avoid strong CYP2D6 inhibitors as their endoxifen concentrations are similar to CYP2D6 poor metabolizers. The utility of endoxifen concentrations and which threshold to consider in clinical practice remains unclear. Ultimately, the clinical impact of mild or moderate CYP2D6 inhibitors on CYP2D6 normal or intermediate metabolizer depends on the endoxifen threshold applied."

Journal • Breast Cancer • Oncology • Solid Tumor

Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. (PubMed, J Clin Oncol) - "Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer."

Journal • P3 data • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN'S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC) (IGCS 2025) - P2/3 | " This international phase 2/3 trial randomly assigned (1:1) patients with recurrent LGSOC to receive either oral trametinib 2 mg once daily (n=130) or one of five SoC treatment options (n=130): intravenous paclitaxel 80 mg/m² by body surface area on days 1, 8, and 15 of every 28-day cycle; intravenous pegylated liposomal doxorubicin 40–50 mg/m² once every 4 weeks; intravenous topotecan 4 mg/m² on days 1, 8, and 15 of every 28-day cycle; oral letrozole 2·5 mg once daily; or oral tamoxifen 20 mg twice daily. At the time of the final analysis, 29 (22.3%) patients in the trametinib arm and 15 (11.5%) patients in the SoC arm remained alive. The median OS was 36.4 months in the trametinib arm versus 29.8 months in the SoC arm (HR 0.68; 95% CI 0.49-0.94; p=0.018, 1-sided), despite the fact that 72% of patients in the SoC arm crossed over to trametinib following progression. In the 93 SoC patients who crossed over to trametinib the median PFS..."

Clinical • Late-breaking abstract • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor (SABCS 2025) - P3 | "Methods Pts who had ER+, HER2- aBC with disease progression (PD) post-CDK4/6i + ET in the aBC setting, or relapse during/after CDK4/6i + ET in the adjuvant setting, were randomized 1:1 to once-daily oral 30 mg GIRE + 10 mg E or SOC ET (exemestane, fulvestrant, or tamoxifen) + E until PD or unacceptable toxicity. Conclusions GIRE + E led to clinically meaningful improvements in INV-PFS vs SOC ET + E irrespective of PIK3CAm and PIK3CA/AKT1/PTEN alt, and other key relevant subgroups, regardless of ESR1m status. These data support the use of GIRE + E vs SOC ET + E in pts with ER+, HER2- aBC post-CDK4/6i + ET."

Biomarker • Clinical • Metastases • P3 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PIK3CA • PTEN

Tamoxifen-loaded TPGS-PLGA nanoplatform for breast cancer therapy: insights into drug delivery, distribution, treatment efficacy, and ultrasound/photoacoustic imaging. (PubMed, Nanomedicine (Lond)) - "The developed TAM@TPGS-PLGA-NPs demonstrated enhanced drug release in the tumor microenvironment, significantly improved cytotoxicity, and excellent biocompatibility compared to the free drug. These findings indicate their strong potential for tumor-targeted breast cancer therapy with reduced systemic toxicity and enhanced therapeutic efficacy."

Journal • Breast Cancer • Oncology • Solid Tumor

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - P1 | N=198 | Active, not recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • CDK6 • HER-2

nextMONARCH 1: A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (clinicaltrials.gov) - P2 | N=234 | Active, not recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Stage IVB ovarian carcinosarcoma in BRCA wild-type patients: two case reports of unexpected long-term remission. (PubMed, Front Oncol) - "Post-recurrence, she received off-label maintenance with tamoxifen 20 mg daily for five years and remains disease-free at 70 months...Postoperative chemotherapy with carboplatin-paclitaxel was followed by maintenance niraparib 100 mg twice daily for three years...Complete cytoreductive surgery combined with tailored systemic and maintenance therapies can achieve sustained remission even in advanced-stage BRCA-wild-type patients. Broader molecular profiling and international collaboration are essential to refine management strategies for this rare and aggressive malignancy."

Journal • Carcinosarcoma • Epithelial Ovarian Cancer • Gynecology • Hepatocellular Cancer • Oncology • Ovarian Cancer • Pulmonary Disease • Respiratory Diseases • Sarcoma • Solid Tumor • BRCA • ER

Neoadjuvant endocrine therapy and avelumab with or without palbociclib in stage II/III endocrine receptor-positive breast cancer: the ImmunoADAPT trial (SABCS 2023) - " In this randomized phase 2 pilot study, pts with stage II/III ER+, HER2-negative breast cancer were randomized 2:1 to ET (aromatase inhibitor, AI, for post-menopausal pts; tamoxifen+/-ovarian function suppression for pre-menopausal pts) with avelumab, with or without palbo (palbo vs. control arms). As shown in previous studies, the addition of palbo to ET did not improve responses in the neoadjuvant setting; however, increased responses to palbo+ET were seen after PD-L1 inhibition, whereas not to ET, suggesting synergy between ET/palbo and avelumab. Translational correlative analysis will aim to decipher TME changes that augment PD-L1 inhibitor responses. Future studies in high-risk pts, where the toxicity of immunotherapy is acceptable, are warranted."

Clinical • IO biomarker • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • CCR10 • ER • HER-2

PI3K inhibition in combination with tamoxifen in patients with metastatic HR+/HER2- breast cancer: clinical and circulating tumor DNA results. (PubMed, Clin Cancer Res) - "Our findings suggest efficacy of PI3K inhibition + tamoxifen beyond second-line treatment and after prior targeted therapies, including CDK4/6 inhibition in metastatic HR+/HER2- breast cancer although the magnitude of benefit did not outweigh the tolerability of this combination. Exploratory biomarker analysis indicates that tumor fraction determined in ctDNA differentiates patients based on prognosis and may help to optimize patient selection for targeted treatment strategies."

Circulating tumor DNA • Journal • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • HER-2

Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen. (PubMed, Ann Surg Oncol) - "Adherence to endocrine prevention is high in women who initiate medication, with few discontinuing due to side effects."

Journal • Real-world evidence • Oncology • Solid Tumor